Global Life Science Ventures

Total investments

31

Average round size

20M

Portfolio companies

21

Rounds per year

1.19

Lead investments

9

Follow on index

0.32

Exits

14

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsManufacturingMedical DeviceMedicalLife SciencePharmaceuticalTherapeutics

Summary

Global Life Science Ventures is the famous VC, which was founded in 1996. The company was established in Europe in Germany. The main office of represented VC is situated in the Mu00fcnchen.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Global Life Science Ventures, startups are often financed by Alta Partners, Gilde Healthcare, Canaan Partners. The meaningful sponsors for the fund in investment in the same round are Gilde Healthcare, Alta Partners, Forbion Capital Partners. In the next rounds fund is usually obtained by Gilde Healthcare, Van Herk Ventures, Thuja Capital.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Genetics, Marketing. Among the various public portfolio startups of the fund, we may underline Agendia, Coapt Systems, Binx Health The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager.

The top activity for fund was in 2003. The typical startup value when the investment from Global Life Science Ventures is 5-10 millions dollars. The real fund results show that this VC is 10 percentage points more often commits exit comparing to other companies. The usual things for fund are deals in the range of 10 - 50 millions dollars. Comparing to the other companies, this Global Life Science Ventures performs on 14 percentage points more the average number of lead investments. The higher amount of exits for fund were in 2005. The fund is constantly included in less than 2 investment rounds annually.

The overall number of key employees were 2.

Show more

Investments analytics

Analytics

Total investments
31
Lead investments
9
Exits
14
Rounds per year
1.19
Follow on index
0.32
Investments by industry
  • Biotechnology (27)
  • Health Care (18)
  • Medical (17)
  • Pharmaceutical (10)
  • Health Diagnostics (6)
  • Show 15 more
Investments by region
  • United States (10)
  • Switzerland (6)
  • Germany (6)
  • Netherlands (3)
  • Austria (1)
  • Show 3 more
Peak activity year
2004

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
21
Avg. valuation at time of investment
32M
Group Appearance index
0.97
Avg. company exit year
10
Avg. multiplicator
0.98

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Espresso Controle de Despesas 01 Jan 2016 Software, FinTech, B2B, Mobile, Finance, SaaS, Apps Seed Minas Gerais, Uberlândia, Brazil
Intercell 18 Jul 2003 Biotechnology, Health Care, Medical Late Stage Venture 50M Austria, Vienna
NeurogesX 24 Feb 2004 Biotechnology, Medical Device, Medical, Neuroscience Late Stage Venture 35M United States, California

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.